This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MYOK MyoKardia (MYOK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About MyoKardia Stock (NASDAQ:MYOK) 30 days 90 days 365 days Advanced Chart Get MyoKardia alerts:Sign Up Key Stats Today's Range$224.91▼$224.9150-Day Range$222.81▼$224.9152-Week Range$42.65▼$225.00VolumeN/AAverage Volume752,969 shsMarket Capitalization$11.99 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California. Read More Receive MYOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MyoKardia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYOK Stock News HeadlinesFulcrum Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:FULC | BenzingaMarch 27, 2025 | benzinga.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024November 13, 2024 | markets.businessinsider.comRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors. | Investors Alley (Ad)Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide MoatNovember 12, 2024 | morningstar.comMHealthEx Raises $14M led by General Catalyst to Empower Patients and Health Systems to do more with Health DataOctober 21, 2024 | markets.businessinsider.comMavacamten Shows Promise in Heart Failure With Normal to Supranormal EFOctober 1, 2024 | msn.comBristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)September 27, 2024 | seekingalpha.comSepterna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development RolesSeptember 25, 2024 | finance.yahoo.comSee More Headlines MYOK Stock Analysis - Frequently Asked Questions How were MyoKardia's earnings last quarter? MyoKardia, Inc. (NASDAQ:MYOK) announced its earnings results on Thursday, November, 5th. The biotechnology company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.44) by $0.16. What other stocks do shareholders of MyoKardia own? Based on aggregate information from My MarketBeat watchlists, some other companies that MyoKardia investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Micron Technology (MU) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/05/2020Today9/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:MYOK CIK1552451 Webwww.myokardia.com Phone650-741-0900FaxN/AEmployees318Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$276.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.99% Return on Assets-42.42% Debt Debt-to-Equity RatioN/A Current Ratio21.03 Quick Ratio21.03 Sales & Book Value Annual Sales$33.56 million Price / Sales357.36 Cash FlowN/A Price / Cash FlowN/A Book Value$8.79 per share Price / Book25.59Miscellaneous Outstanding Shares53,323,000Free FloatN/AMarket Cap$11.99 billion OptionableOptionable Beta1.84 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:MYOK) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyoKardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyoKardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
